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Abstract
Background: Pelargonium sidoides DC (Geraniaceae) root extract, EPs®7630 or “Kaloba®”, is a widely used herbal
remedy for respiratory infections, with some evidence of effectiveness for acute bronchitis. However, it is not yet
widely recommended by medical professionals in the UK. There is a need to undertake appropriately designed
randomised trials to test its use as an alternative to antibiotics. The aim was to assess the feasibility of conducting a
double-blind randomised controlled trial of Pelargonium sidoides root extract for treatment of acute bronchitis in UK
primary care, investigating intervention compliance, patient preference for dosage form and acceptability of patient
diaries.
Study design: Feasibility double-blind randomised placebo-controlled clinical trial.
Methods: We aimed to recruit 160 patients with cough (≤ 21 days) caused by acute bronchitis from UK general
practices. Practices were cluster-randomised to liquid or tablet preparations and patients were individually
randomised to Kaloba® or placebo. We followed participants up for 28 days through self-reported patient diaries
with telephone support and reviewed medical records at one month. Outcomes included recruitment, withdrawal,
safety, reconsultation and symptom diary completion rates. We also assessed treatment adherence, antibiotic
prescribing and consumption, mean symptom severity (at days 2–4 after randomisation) and time to symptom
resolution. We interviewed 29 patients and 11 health professionals to identify barriers and facilitators to running
such a randomised trial.
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Results: Of 543 patients screened, 261 were eligible, of whom 134 (51%) were recruited and 103 (77%) returned a
completed diary. Overall, 41% (41/100) of patients took antibiotics (Kaloba® liquid group: 48% [15/31]; placebo liquid
group: 23% [6/26]; Kaloba® tablet group: 48% [9/21]; placebo tablet group: 50% [11/22]). Most patients adhered to
the study medication (median 19 out of 21 doses taken in week 1, IQR 18–21 - all arms combined). There were no
serious adverse events relating to treatment. Most patients interviewed found study recruitment to be
straightforward, but some found the diary too complex.
Conclusions: It was feasible and acceptable to recruit patients from UK primary care to a double-blind placebo-
controlled trial of herbal medicine (Kaloba®) for the treatment of acute bronchitis, with good retention and low
data attrition.
Trial registration: HATRIC was registered on the ISRCTN registry (ISRCTN17672884) on 16 August 2018,
retrospectively registered. The record can be found at http://www.isrctn.com/ISRCTN17672884.
Keywords: Feasibility clinical trial, Double-blind randomised, Placebo-controlled, Acute bronchitis, Cough, Herbal
medicine, Retention, Cluster-randomised
Background
Reducing antibiotic resistance is a national and inter-
national priority, and the UK aims to reduce antibiotic
use in humans in the community by 25% by 2024, from
the 2013 baseline [1]. National levels of antibiotic resist-
ance correlate with rates of antibiotic prescriptions [2]
and reducing primary care consumption is associated
with reduced resistance [3]. At an individual level, risk
of antibiotic-resistant infection is over twice as high if an
antibiotic has been taken in the past year [4] and this in-
creases the risk of clinical treatment failure [5]. Another
important reason to reduce use of antibiotics is the side-
effects that they cause; for example nausea, rash and
diarrhoea were significantly more common in patients
receiving antibiotics for acute bronchitis than in patients
receiving placebo [6]. In spite of this, and although they
have very little effect on the clinical course of acute
bronchitis [6, 7], 82% of patients with acute bronchitis in
the UK continue to receive an antibiotic prescription,
compared to an “ideal” level of 13% [8].
Several strategies have attempted to reduce inappro-
priate use of antibiotics. “Delayed” prescriptions (which
patients are advised to take only if they are not starting
to improve after a certain time) reduce consumption of
antibiotics while maintaining patient satisfaction [9], but
many patients would still like to take medication to re-
lieve their symptoms because a moderately bad cough is
known to persist for around three weeks on average [6,
10]. Commonly recommended treatments like steam
and ibuprofen make little or no difference to symptom
severity [11]. Other potential symptomatic treatments in
adults (the expectorant guaifenesin, mucolytics and
antihistamine-decongestant combinations) have not
been shown to have consistent benefit in a recently up-
dated Cochrane systematic review [7].
Herbal medicine is another option for relieving symp-
toms and so reducing inappropriate use of antibiotics
[12]. Qualitative research has shown that herbal medi-
cine is widely used and accepted as a viable option for
treatment of mild respiratory infections, especially by
ethnic minorities, but very few studies have included
white Caucasian adults [13–16]. Many patients feel that
they need trustworthy advice on whether to use alterna-
tive treatments, which to use, and when [17].
Of all the available herbal remedies for respiratory in-
fections, Pelargonium sidoides DC (Geraniaceae) is one
of the few which already have some evidence of efficacy.
It has been used traditionally in South Africa for over a
century, both for diarrhoea and for tuberculosis. The
first European to “discover” this medicinal plant was
Charles Stevens, who was advised by his doctor to go to
South Africa after he was diagnosed with tuberculosis.
He consulted a traditional healer who treated and cured
him with a root decoction [18]. So convinced was he of
its effectiveness that he started marketing it in England
for treatment of TB in 1904 and it also became widely
used in France and Switzerland, where many cases were
described of patients with TB who improved after taking
this remedy [18, 19]. Stevens kept the identity of the
plant secret, and it was not identified until the 1970s
[20]. “Umckaloabo” has been marketed in Europe for the
treatment of bronchitis since 1991 [20]. It is now widely
available over the counter: 990 million defined daily
doses of EPs®76301 were placed on the market between
1992 and 2016 (defined daily dose: solution: 4.5 ml,
syrup: 11 ml, or 3 tablets, respectively; data from the
pharmaceutical manufacturer, 2018).
There are plausible mechanisms to support the poten-
tial effect of Pelargonium sidoides. Although the root ex-
tract EPs® 7630 has only weak antibacterial activity [21]
it activates macrophages [22, 23] and reduces binding of
1EPs® 7630 is the active ingredient of the product Kaloba® (ISO
Arzneimittel Ettlingen)
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group A streptococci to human epithelial cells [24, 25].
It is also active against several respiratory viruses [26,
27] and reduces viral infection of human broncho-
epithelial cells by down-regulating cell membrane dock-
ing proteins and up-regulating host defence proteins
[28]. In mouse and guinea pig models, it has an antitus-
sive effect [29].
Several clinical trials and a Cochrane review have
concluded that Pelargonium sidoides root extract may
be effective at relieving symptoms of acute bronchitis
in both adults and children, but the overall quality of
the evidence was considered low [30]. Three small
randomised controlled trials in acute bronchitis in
adults were included and showed inconsistent but
overall positive results for resolution of symptoms (all
symptoms, cough and sputum production). Three
additional studies in acute bronchitis in children were
included showing similar inconsistent but positive
findings. In adults, symptoms were consistently im-
proved after seven days with an effect observed in in-
dividual scale items after 4 days. In a review of the
bronchitis severity score (BSS), which included 17
studies of Pelargonium sidoides (11 adult and 8
children) a difference in BSS was seen by day 3–5
[31]. The Cochrane review suggested that the liquid
formulation may be more effective than the tablets al-
though the number of trials was insufficient to prove
this. All the studies included in the review of the BSS
showed symptomatic improvement following treat-
ment with Pelargonium sidoides regardless of dosage
form [31]. Pelargonium sidoides tablets are available
in the UK and are likely to be more readily available
internationally than liquid preparations but it is not
clear whether liquid preparations are potentially more
efficacious. There is no direct comparative data on
tablet and liquid formulations and hence some there
is uncertainty over their relative acceptability for
consumption.
In the UK, the National Institute for Health and Care
Excellence (NICE) suggests that some people may wish
to try Pelargonium as a “self-care treatment”, which has
“limited evidence of some benefit for the relief of cough
symptoms” [32]. There is currently sufficient evidence to
recommend the use of Pelargonium sidoides root extract
to warrant undertaking a high quality independent
clinical trial.
The aim of this study was to determine the feasibility
of conducting an adequately powered randomised trial
of Pelargonium sidoides root extract as an alternative to
antibiotics for acute bronchitis in UK primary care. The
study is called the “HATRIC” trial (Herbal Alternative
Treatment for lower Respiratory tract Infections with
Cough in adults). A qualitative study, “HATRIC-Q”, was
undertaken with a subset of participants and health
practitioners involved in the HATRIC trial to explore
the feasibility of implementing a full clinical trial and use





We conducted a phase II double-blind feasibility trial
with UK GP practices cluster-randomised to give liquid
or tablet preparation (for logistical reasons), and within
each practice, eligible patients were individually rando-
mised to Pelargonium sidoides root extract (EPs®7630 –
Kaloba®) or matched placebo. The detailed protocol for
this trial has already been published [33]. This trial ad-
heres to CONSORT guidelines.
Participants
We recruited patients from 20 GP practices in southern
England. We included adults aged 18 years and over,
presenting to their GP with an acute cough (≤21 days’
duration) as their main symptom, and with symptoms
localising to the lower tract (e.g. sputum, chest pain, dys-
pnoea, wheeze). This illness definition has been used in
other studies in this population [6, 34]. We excluded pa-
tients with suspected pneumonia on the basis of focal
chest signs (focal crepitations, bronchial breathing) and
systemic features (severe breathlessness, high fever,
vomiting, severe diarrhoea), patients with serious illness
who required hospital admission, exacerbations of
COPD, serious comorbidities, and pregnant women (or
at risk of pregnancy – defined as any woman of repro-
ductive age not using the combined oral contraceptive
pill, a hormonal intrauterine device, a hormonal contra-
ceptive injection, or a subcutaneous hormonal implant).
Eligible patients were invited to participate in the trial
by their GP or nurse and were given a patient informa-
tion sheet during their GP appointment. If they con-
sented, they were then given the study medication and
the study diary on the spot and were advised that a trial
coordinator would be in touch soon regarding their
diary. The randomisation list for sites and patients was
generated by Southampton Clinical Trials Unit using the
command ralloc in Stata v15 [35]. We used block ran-
domisation (with varying block size) in a 1:1 allocation
ratio of placebo to Kaloba® treatment. Treatment packs
were sent to sites in sets of four and each patient was al-
located the next available sequentially numbered patient
pack at their site. Neither the patient nor the doctor or
nurse knew to which treatment (Kaloba® or placebo)
they had been randomised. Patients were free to with-
draw consent from the study at any time without provid-
ing a reason.
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Interventions
Patients on experimental treatment were given a root
extract of Pelargonium sidoides DC (Geraniaceae). The
product used was EPs®7630, manufactured by Dr. Will-
mar Schwabe GmbH & Co. KG, Germany (named
Kaloba®). The extraction solvent used was 11% ethanol
(w/w), such that 10 g (= 9.75mL) of oral solution con-
tains 8.0 g extract from the roots of Pelargonium sidoides
DC (1: 8–10), and one film-coated tablet contains 20 mg
of extract (as dry extract, 1: 8–10). The verum medica-
tion provided for the study is taken from production lots
sold in the market. All test methods and specifications
for the materials, intermediates and the final product are
part of the registration dossier and therefore approved
by the respective authorities. The liquid also contained
glycerol and ethanol (120mg / 1 ml). The tablets con-
tained the following excipients: Maltodextrin, microcrys-
talline cellulose, lactose monohydrate, croscarmellose
sodium, precipitated silica, magnesium stearate, and the
film coating (hypromellose, macrogol, iron oxide yellow
E172, iron oxide red E172, titanium dioxide E171, talc,
simeticone, methylcellulose and sorbic acid).
The extract was obtained from dried roots of Pelargo-
nium sidoides extracted with 11% ethanol w/w, resulting
in a drug extract ratio of 1: 8–10 for the liquid extract
and the dry extract as well (obtained from the liquid
extract by drying). Roots of Pelargonium sidoides were
collected in South Africa (e.g. Eastern Cape). The dried
material was tested in an array of phytochemical and
biochemical methods to confirm the quality and identity
of the herbal material. Pharmacognosy was done by the
quality control department of Dr. Willmar Schwabe
GmbH & Co. KG, Germany (Dr. H. Hentrich and lab
technicians specifically skilled in pharmacognostic test
procedures). A voucher specimen of every lot is depos-
ited in the department of Pharmacognosy to be retained
for ten years. In addition, the herbal material is tested
with respect to purity (e.g. heavy metals, and microbio-
logical quality).
Quality testing
The extract (EPs® 7630) used in the herbal medicinal
product (Kaloba® manufactured by Dr. Willmar Schwabe
GmbH & Co. KG, Germany) is classified by the Euro-
pean Pharmacopoeia as “other extract” and therefore not
adjusted to a particular content of constituents. Inde-
pendent of this formal classification, the constituents of
this herbal active ingredient have been described in de-
tail [36]. Approximately 80% m/m of the extract are
assigned to six major groups of constituents, oligomeric
prodelphinidines (commonly designated in this context
as polyphenols) being the most significant group (ap-
proximately 40% of the dried extract).
The liquid herbal medicinal product used in the study
(Kaloba® manufactured by Dr. Willmar Schwabe GmbH
& Co. KG, Germany) is tested and released compliant
with drug GMP and the European Pharmacopoeia ac-
cording to written, authorized and validated analytical
procedures with respect to identity, content (ethanol,
glycerin, extract; HPLC) and microbiological quality.
The film-coated tablets are tested with the same
methods, adapted to the respective dosage form with re-
spect to extract content (HPLC), uniformity, disintegra-
tion and microbiological purity. The respective placebo
preparation is tested with the same procedures, except
for herbal drug content (i.e. absence of active ingredient)
and in addition for visual appearance in comparison to
the batch of herbal drug product used as medication.
The quality testing is performed by the Quality Control
laboratory of Dr. Willmar Schwabe GmbH & Co. KG,
Germany by a laboratory technician with extensive long-
term experience in the testing of herbal medicinal prod-
ucts. Personnel manufacturing or performing quality
tests on investigational medicinal products including
placebo preparations have been specifically skilled and
trained in this field.
The liquid placebo was designed to match the appear-
ance of the liquid herbal medicinal product. This was
achieved by using the identical solvent composition
(water, glycerol, ethanol) and by replacing the herbal
active ingredient with colouring and flavouring. The
placebo tablets were also designed to match the appear-
ance of the active tablets, by using the identical film-
coating composition and a coloured granulation for
manufacturing of the uncoated tablets matching the tab-
let core of the herbal medicinal product.
The dosage of the liquid (Kaloba® or placebo) was 30
drops (approximately 1.5 ml) three times daily, to be
taken 30min before meals. For tablets (Kaloba® or pla-
cebo), the dose was one 20 mg tablet three times daily,
to be taken 30 min before meals. Patients were advised
to continue this treatment daily until 2–3 days after
symptoms had resolved but that treatment duration
should not exceed 2 weeks. This is the dosage recom-
mended by the manufacturer and on the traditional
herbal registration.
In addition to the trial treatment, GPs were allowed to
select the clinically appropriate prescribing strategy as
per practice policy, no antibiotics or to prescribe antibi-
otics, either to be taken immediately, or as a “delayed”
prescription.
Outcomes
Baseline data were collected at the GP practices where
patients were recruited, and medical records were
reviewed after one month to extract data on NHS re-
source usage. Patients were given a diary to complete for
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4 weeks, including their symptoms, treatments taken,
out-of-pocket expenditure, days off work related to their
acute bronchitis and quality of life measurements
(EQ5D). All patients were asked to complete the EQ-
5D-5L questionnaire at baseline (day 1) and day 7 and
approximately half of the patients were also randomly
selected to be given the questionnaire at additional time
points on days 2 and 4, in order to assess the acceptabil-
ity of collecting quality of life data more frequently. Pa-
tients were telephoned at day 1 or 2 to check for any
problems with diary completion, and again at days 14
and 28 days to prompt diary completion and return. If
diaries were not returned, or were returned incomplete,
a brief telephone interview to collect the key data was
undertaken after 35 days.
Feasibility outcomes were: recruitment rate, with-
drawal rate from the study, return rate of patient diaries,
percentage of completion of patient diaries, compliance
with medication according to diary data and returned
medication, type of antibiotic prescription given (i.e. im-
mediate/delayed/not given), percentage of patients who
took antibiotics, time to antibiotic usage, mean symptom
severity (at days 2–4), percentage of patients resolved,
time to resolution of symptoms and duration of treat-
ment with herbal medication. The minimum key out-
come dataset from the diaries was considered to be [1]
antibiotic use in the 28 days post randomisation, [2] no
longer experiencing moderate symptoms for two con-
secutive days and [3] study medication use. A health
economic study was a part of the feasibility study which
aimed to develop the methods of data collection both
for quality of life and for usage of key resources for the
design of the future phase III trial.
We explored several possible outcome measures for
clinical effectiveness (Table 3). “Duration of symptoms
rated as moderately bad or worse” was used in the lar-
gest clinical trial of treatment for acute bronchitis [6].
The “last day” definitions allow for the possibility that
the illness may fluctuate in severity over the 28-day
period and the “first day” definitions do not. Therefore,
the last day will tend to be later than or equal to the first
day. “Proportion of patients with symptom resolution at
day 7” was used in the Cochrane review [30].
Statistical methods
The intended sample size was 160 patients overall (40
patients in each of the 4 arms) recruited from 20 GP
practices in the UK. No formal sample size calculation
was carried out however, ignoring clustering, using a
95% confidence interval approach and an expected pro-
portion of 50% of eligible patients randomised into the
trial (to give the worst-case scenario), it can be shown
that this sample size would allow us to predict the re-
cruitment rate to within 8% using nQuery Advisor v7.0.
Accounting for the clustering based on an intra-cluster
correlation (ICC) of 0.05 and an expected proportion of
50% of eligible patients randomised into the trial, this
sample size allows us to predict the recruitment rate
(number of eligible patients randomised into the trial) to
within 13%, given an average cluster size of 8, and 20
recruiting sites.
A detailed statistical analysis plan was developed prior
to the analysis. All analyses were conducted using
STATA version 15 [35]. We aimed to present descriptive
feasibility data rather than to test hypotheses and pa-
tients were analysed as randomised.
Health economic methods
The economic study was designed from the NHS and a
Personal Social Service perspective. In addition, we col-
lected personal costs to test whether a societal perspec-
tive should be considered in future trials. Key resources
included the costs of the intervention and NHS service
use including medication, primary care consultation,
outpatient attendance, A&E visits, and hospitalisation.
Data on NHS resource usage was extracted through a
review of medical records in the 28 days following re-
cruitment. Out-of-pocket spending and days off work re-
lated to lower respiratory tract infection were collected
through patients’ self-reported diaries. Quality of life
data were measured by giving the EQ-5D-5L question-
naire to all patients at baseline (Day 1) and Day 7 and
half of the patients were randomly asked to complete
the questionnaire at additional time points on Day 2 and
Day 4. This aimed to assess the acceptability of more
frequently collecting quality of life data in future trials.
HATRIC-Q nested qualitative study
We conducted a nested qualitative study of patients who
met inclusion criteria (including those who did not con-
sent to participate in the clinical trial) and health profes-
sionals. Patients were asked for their consent to pass
their contact details to the qualitative researcher, who
contacted them by telephone to conduct a semi-
structured interview, using an interview guide. Health
professionals were invited by email. Consent was re-
ceived verbally by telephone. We aimed for a maximum
variation sample, based on pre-specified criteria, such as
ethnicity, gender, age, employment status, site, trial drug
(liquid drops or tablets), diary status (complete, partly
completed, by recall, not returned), and recruitment per-
formance (for the staff interviews). The patients and
health professionals who had participated in the trial
were asked about trial materials and trial procedures,
while those patients who declined to participate were
asked for their reasons for non-participation. Interviews
were audio-recorded and transcribed verbatim. We also
explored the interviewees’ experience of LRTI and its
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treatment with antibiotics, as well as their attitudes to-
wards delayed prescribing of antibiotics and their views
on herbal medicine. Only the results pertinent to trial
design are reported here.
Transcripts were analysed using inductive thematic
analysis, following the framework approach [37]. The
transcripts were compared within and between each
other to search for themes, which were then reviewed,
defined and named. The analysis followed three key
steps:
1. Familiarization: repeated readings of transcripts
and listening to recordings assisted familiarisation
with the data, identification of initial codes and
interesting pieces of data
2. Categorization: grouping similar responses into
meaningful categories
3. Classification: assessing relationships between
categories and more abstract grouping in order to
explain the data
Standard methods were used to safeguard rigor, in-
cluding multiple coding by DS, RY, MW and GL to
check the validity and consistency of coding.
Ethical and other approvals
HATRIC was registered on the ISRCTN registry (ISRC
TN17672884) on 16 August 2018.
Results
HATRIC trial – quantitative results
Patients were recruited from March to December 2018,
with follow-up ending in January 2019. Five hundred
and forty three patients were screened of whom 261
were initially assessed as eligible and 134 (51%) were
randomised into the study (Fig. 1). The trial ended after
9 months (rather than the planned 12 months) because it
had been 6months late in starting; over these 9 months
it was possible to recruit over 80% of the sample size
planned for the 12-month recruitment period.
Of the 127 eligible patients not randomised, in 69
cases this was because the patient declined, and 51 of
these gave a reason. Most frequent were concerns about
the medication (21/51 patients: 5 didn’t want a placebo;
5 were concerned about potential side-effects; 4 didn’t
want to take more medicines; 2 didn’t want a herbal
medicine; 2 did not want the liquid preparation; 1 did
not want the tablets; 2 wanted antibiotics). Second most
frequent (12/51) were patients who were too busy to
participate or had personal circumstances which would
make it difficult (planned holiday, unwell family mem-
ber). Nine patients felt either that they were too unwell
to take part [6] or that they were improving and didn’t
need to take anything [2] or that taking part would make
them too anxious [1]. Three patients stated that they just
didn’t want to be involved in research. Five patients spe-
cifically mentioned that they wouldn’t be good at com-
pleting the diary and one would have had to travel to
another branch surgery of his GP practice to be
recruited.
Of the 134 randomised patients, 82 were allocated to
liquid (Kaloba® [n = 42] or placebo [n = 40]) and 52 to
tablets (Kaloba® [n = 26] or placebo [n = 26]). During the
study period, three patients chose to withdraw – two
from the liquid Kaloba® group, one from the liquid pla-
cebo group. One patient in the Kaloba® tablet group died
due to reasons unrelated to the trial. After completing
the trial, four patients were found to have been ineligible
because they were women of reproductive age who were
using a contraceptive which was not included in the list
of the “most effective” contraceptives specified in the
protocol. None of these were or subsequently became
pregnant during the trial or experienced any adverse
events. As the details of their contraception were only
confirmed after they had completed the trial, their data
is included in the analyses below, as were the data of all
the withdrawn patients. The CONSORT diagram is
given in Fig. 1.
Recruited patients were primarily white with an aver-
age age of 56–59 years (Table 1). Median duration of
cough and illness prior to consultation ranged from 6 to
9 days in the different groups. On average, symptom se-
verity at baseline was moderately bad or bad for cough,
phlegm and feeling generally unwell. Overall 80/134
(59.7%) were not prescribed an antibiotic, 21/134
(15.7%) were prescribed a delayed antibiotic and 33/134
(24.6%) an immediate antibiotic. The cluster randomisa-
tion did not produce a balanced pattern of antibiotic
prescription, as practices allocated to the “tablet” groups
prescribed more antibiotics (53.8 and 46.2%) than those
allocated to the liquid groups, and within the liquid arm,
by chance more patients on the Kaloba® liquid received
antibiotics (40.4%) than patients on the placebo liquid
(27.5%). More of those in the “tablet” groups received
delayed prescriptions, whereas in the liquid groups, most
received immediate antibiotics. According to their diar-
ies, 41% (40/100) of patients took antibiotics (liquid
Kaloba® group: 48% [15/31]; liquid placebo group: 23%
[6/26]; tablet Kaloba® group: 48% [9/21]; tablet placebo
group: 50% [11/22]).
Of the 134 randomised patients, 103 returned their
diaries (76%) and a further 12 (9%) were completed by
recall over the telephone. Initially, 47/103 (46%) of the
returned diaries were complete, whereas 56 (54%) had
key information missing. These patients were contacted
by telephone and key information was completed for an
additional 48/54 patients. Therefore, overall we obtained
the key outcome dataset for 107/134 patients (80%),
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Fig. 1 CONSORT diagram
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while no diary was received for 19 (14%), and incomplete
diaries for 8 (6%).
Of 134 participants, 45 (34%) were given EQ-5D-5L at
two time points (baseline and 7 days), 89 (66%) were
asked to complete it at 4 points (baseline, 2 days, 4 days
and 7 days). The completion rates for two points were
69% (31/45) and 67% (30/45) for baseline and 7 days re-
spectively. The completion rates at 4 points in time were
76% (68/89), 76% (68/89), 73% (65/89) and 69% (61/89)
at baseline, day 2 and day 4 and day 7, respectively. The
completion rates were slightly higher for the group
asked to complete EQ-5D-5L at 4 time points. This indi-
cates that more frequent completion of the EQ-5D-5L
questionnaire was acceptable in the study population.
Adherence to the study medication proved difficult to
measure, because there was not a standard duration of
treatment: patients were advised to take the study medi-
cation three times daily and to stop 2–3 days after their
symptoms resolved (which is subjective). There were no
pronounced differences between groups in the propor-
tion who stopped in the first week or two, or who
stopped before they had recovered (Table 2). Overall,
the median number of doses taken in the first week was
19 (IQR 18–21); ideal would have been 21. This was
consistent across the four groups and suggests that
treatment adherence was good in all groups.
This feasibility study was not powered to detect a dif-
ference between groups in the time for recovery of
symptoms. However, the results appear compatible with
the effect size reported in the Cochrane review [30] with
those on Kaloba® recovering sooner than those on pla-
cebo (Table 3). The last day of all moderately bad










Female 19/42 (45.2%) 26/40 (65.0%) 15/26 (57.7%) 16/26 (61.5%) 76/134 (56.7%)
Mean age (SD) 56.64 (14.41) 56.65 (17.24) 59.23 (12.31) 57.27 (17.89) 57.27 (15.52)
Ethnicity
➙White 30/31 (96.8%) 27/27 (100.0%) 20/21 (95.5%) 21/22 (95.5%) 98/101 (97.0%)
➙Mixed 0/31 (0.0%) 0/27 (0.0%) 0/21 (0.0%) 1/22 (4.6%) 1/101 (1.0%)
➙Asian/Asian-British 1/31 (3.2%) 0/27 (0.0%) 0/21 (0.0%) 0/22 (0.0%) 1/101 (1.0%)
➙Prefer not to answer 0/31 (0.0%) 0/27 (0.0%) 1/21 (4.6%) 0/22 (0.0%) 1/101 (1.0%)
Employment
➙Full/part time 18/31 (58.1%) 13/26 (50.0%) 10/21 (47.6%) 11/22 (50.0%) 52/100 (52.0%)
➙Unable to work 1/31 (3.2%) 1/26 (3.9%) 1/21 (4.8%) 0/22 (0.0%) 3/100 (3.0%)
➙Retired 11/31 (35.5%) 11/26 (42.3%) 10/21 (47.6%) 11/22 (50.0%) 43/100 (43.0%)
➙Full time education 0/31 (0.0%) 1/26 (3.9%) 0/21 (0.0%) 0/22 (0.0%) 1/100 (1.0%)
➙Not working for other reasons 1/31 (3.2%) 0/26 (0.0%) 0/21 (0.0%) 0/22 (0.0%) 1/100 (1.0%)
Smoking habits
➙Never 15/30 (50.0%) 11/27 (40.7%) 7/21 (33.3%) 10/22 (45.5%) 43/100 (43.0%)
➙Past 14/30 (46.7%) 14/27 (51.9%) 13/21 (61.9%) 8/22 (36.7%) 49/100 (49.0%)
➙Current 1/30 (3.3%) 2/27 (7.4%) 1/21 (4.8%) 4/22 (18.2%) 8/100 (8.0%)
Health conditions
➙Hypertension 11/42 (26.2%) 9/40 (22.5%) 7/26 (26.9%) 4/26 (15.4%) 31/134 (23.1%)
➙CVD 1/42 (2.4%) 3/40 (7.5%) 0/26 (0.0%) 1/26 (3.9%) 5/134 (3.7%)
➙Lung disease/COPD 0/42 (0%) 1/40 (2.5%) 2/26 (7.7%) 0/26 (0%) 3/134 (2.2%)
➙Diabetes 5/42 (11.9%) 3/40 (7.5%) 3/26 (11.5%) 1/26 (3.9%) 12/134 (9.0%)
➙Asthma 9/42 (21.4%) 8/40 (20.0%) 3/26 (11.5%) 3/26 (11.5%) 23/134 (17.2%)
Antibiotic Prescription
➙No 25 (59.5%) 29 (72.5%) 12 (46.2%) 14 (53.8%) 80/134 (59.7%)
➙Delayed Use 3 (7.1%) 3 (7.5%) 7 (26.9%) 8 (30.8%) 21/134 (15.7%)
➙Immediate Use 14 (33.3%) 8 (20.0%) 7 (26.9%) 4 (15.4%) 33/134 (24.6%)
1: Symptom severity was scored 0–6 (0 = Normal/not affected; 1 = Very little problem; 2 = Slight problem; 3 = Moderately bad; 4 = Bad; 5 = Very bad; 6 = As bad as
it could be)
LQ – Lower quartile; UQ – Upper quartile
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symptoms (score 3 or more) was day 7 and 12 in the
Kaloba® and placebo liquid groups respectively, and day
9 in both tablet groups. However, these results are based
on small numbers and do not control for baseline sever-
ity or antibiotic use.
There were two serious adverse events, neither of which
was related to the treatment: a patient in the placebo li-
quid group suffered a myocardial infarction, and a partici-
pant in the Kaloba® tablet group died due to reasons
clearly unrelated to the study. Minor adverse events were
reported by 7/42 (17%) of patients in the Kaloba® liquid
group and in 7/92 (8%) of the other groups (Table 4). The
commonest were cough and phlegm which are most likely
due to the illness, not to the medication.
All patients had an initial primary care consult-
ation when they were recruited into the study and
22% were reconsulted during the follow-up. A small
number (3 in total) used a secondary care service in-
cluding two outpatient attendances and one hospital
admission. 36/134 (27%) of patients reported having
used out of pocket purchases and 24/134 (18%) had
taken time off work due to their illness. This sug-
gests that a societal perspective should be taken in a
future trial.











Stopped in week 1 4/27 (14.8%) 5/25 (20.0%) 3/16 (18.8%) 2/20 (10.0%) 14/88
(15.9%)
Stopped in week 2 14/24 (58.3%) 14/20 (70.0%) 9/16 (56.3%) 15/21 (71.4%) 52/81
(64.2%)
Stopped in week 1 but still experienced
moderately bad symptoms
2/17 (11.8%) 0/16 (0.0%) 1/9 (11.1%) 1/11 (9.1%) 4/53 (7.5%)
Stopped in week 2 but still experienced
moderately bad symptoms
5/9 (55.6%) 6/9 (66.7%) 0/2 (0.0%) 4/7 (57.1%) 15/27
(55.6%)
Stopped in week 1 but had not recovered from all
symptoms
2/20 (10.0%) 2/20 (10.0%) 1/14 (7.1%) 2/17 (11.8%) 7/71 (9.9%)
Stopped in week 2 but had not recovered from all
symptoms
5/10 (50.0%) 6/10 (60.0%) 1/8 (12.5%) 6/10 (60.0%) 18/38
(47.4%)
Median (IQR) doses taken in week 1 20 (17,21) 18.5 (17,20) 19 (18,21) 19 (18, 21) 19 (18,21)
➙Morning 6 (6,7) 6 (5,6) 6 (6,7) 6 (6,7) 6 (6,7)
➙Afternoon 7 (5,7) 6 (5,7) 7 (6,7) 6.5 (5,7) 7 (5,7)
➙Evening 7 (7,7) 7 (6,7) 7 (6,7) 7 (6,7) 7 (6,7)











Last day of any moderately bad symptoms1 7 (4,15) 12 (4,17) 9 (5,13) 9 (4,15) 9 (4,14)
First day of no moderately bad symptoms2 7 (4,8) 8 (4,13) 6.5 (4,11) 8 (5,14.5) 7 (4,11)
Last day of any symptoms 9 (6,17) 13.5 (7,19) 11 (8,14) 12.5 (8,24) 11 (7,17.5)
First day of no symptoms 10 (6,12) 12 (6,17) 7 (6,12) 11 (8,15) 9 (6,14)
Moderately bad symptoms resolved by day 7? 17/31 (54.8%) 9/26 (34.6%) 9/21 (42.9%) 10/22 (45.5%) 45/97
(46.4%)
Moderately bad symptoms resolved by day 14? 23/31 (74.2%) 17/26 (65.4%) 18/21 (85.7%) 16/22 (72.7%) 74/100
(74.0%)
All symptoms resolved by day 7? 10/31 (32.3%) 7/26 (26.9%) 4/21 (19.1%) 5/22 (22.7%) 26/100
(26.0%)
All symptoms resolved by day 14? 22/31 (71.0%) 15/26 (57.7%) 16/21 (76.2%) 14/22 (63.6%) 67/100
(67.0%)
Antibiotics started? 15/31 (48.4%) 6/26 (23.1%) 9/21 (47.6%) 11/22 (50.0%) 41/100
(41.0%)
Days to first dose of antibiotics in those who reported taking
them (median, interquartile range)
1 (1,1) 1 (1,8) 1 (1,9) 1 (1,6) 1 (1,4)
1. The last day of moderately bad symptoms, defined as a score of 3 or more, based on all symptoms recorded in the patient diary
2. The first day without any moderately bad symptoms, a score of 3 or more, based on all symptoms recorded in the patient diary. As severity of symptoms
fluctuates, patients may subsequently experience further days with moderately bad symptoms
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Nested qualitative study results
We contacted 43 patients to invite them to be interviewed.
Of these, we were able to interview 29 patients, 27 of
whom had participated in the HATRIC trial, and two of
whom had been invited but declined to participate. We
also interviewed 11 health professionals who had been in-
volved in recruiting patients into the HATRIC trial.
Study recruitment
Barriers and facilitators to study recruitment are sum-
marised in Table 5. Overall the patients reported that
the recruitment, information sheet and consent process
were straightforward, clear and professional, although a
few mentioned that it was too time-consuming. Most
participants agreed to take part because they wanted to
help the researchers reduce the use of antibiotics, im-
prove their symptoms and trial different options includ-
ing herbal medicine. However, the interviews revealed
that there were a few patients who did not fully under-
stand the purposes and/or some aspects of the trial. One
patient would have liked more explanation around the
use of antibiotics in relation with the study medication.
Another thought that the trial medication ‘is something
that people should be taking sooner rather than later in
their illness… in which case I’m not sure whether or not
taking it so late … was relevant for your research’. Some
patients explained that recruitment took place when
they were feeling poorly, which could have affected their
decision. For example, one participant explained that he
agreed to take part in the trial to ensure he got antibi-
otics and could go home. Two patients explained that
because their GP would not prescribe antibiotics, they
took part because they wanted something for the symp-
toms. Another assumed the antibiotics were part of the
study: ‘she [GP] just gave them [antibiotics] to me, so I
just assumed it’s for the study. That part of it was not
particularly well explained’.
Unfortunately, it proved very difficult to interview pa-
tients who did not agree to participate in the trial. The
two non-participants explained that they were both ini-
tially willing to participate, but one was not eligible and
the second declined due to potential side effects (head-
aches), imminent holiday plans and she was not keen to
commit to filling in a daily diary.











Number of patients that experienced at least one
Side-effect – n (%)1
7 (16.7%) 3 (7.5%) 2 (8.0%) 2 (7.7%) 14 (10.5%)
Total number of Side-effects – n2 28 (68.3%) 8 (19.5%) 3 (7.3%) 2 (4.9%) 41 (100.0%)
Summary of Side-effects – n (%)2
Frequent bouts of Vomiting3 1 (3.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%)
Bad taste in mouth 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (50.0%) 1 (2.4%)
Burping 0 (0.0%) 3 (37.5%) 0 (0.0%) 0 (0.0%) 3 (7.3%)
Cough 4 (14.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (9.8%)
Diarrhoea 1 (3.6%) 0 (0.0%) 1 (33.3%) 0 (0.0%) 2 (4.9%)
Disturbed Sleep 1 (3.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%)
Drowsiness 1 (3.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.4%)
Feeling Bloated 0 (0.0%) 3 (37.5%) 0 (0.0%) 0 (0.0%) 3 (7.3%)
Feeling Unwell 3 (10.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (7.3%)
Headaches 3 (10.7%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 4 (9.8%)
Phlegm 5 (17.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (12.2%)
Muscle Aches 2 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%)
Nausea4 2 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%)
Runny Nose 3 (10.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (7.3%)
Stomach Pain 0 (0.0%) 0 (0.0%) 2 (66.6%) 1 (50.0%) 3 (7.3%)
Upset Stomach 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (2.4%)
Wheeze 2 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (4.9%)
1 Denominator is the number of patients randomised in the study
2 Denominator is number of Side-effects on study
3 Patient initially recorded this over all 4 weeks, however related AE only covers period of first week
4 One patient recorded nausea in Week 1 diary and Week 2 diary, unsure if this is the same event
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From the perspective of the health professionals, the
main barriers to recruitment were limiting and confus-
ing inclusion criteria (particularly regarding women of
reproductive age – exemplified by the fact that four such
women were recruited in error - although they were
using a contraceptive, the protocol specified only 4 types
of contraception which were admissible); the time taken
by the recruitment process; the lengthy patient diary; the
lack of patients with relevant symptoms in the summer;
and a perception that the payment for GPs to participate
in the study was insufficient. The main facilitators to re-
cruitment were patients having a positive attitude to-
wards herbal medicine, and there being several GPs and
nurses involved in the recruitment process in the prac-
tice. Having a triage system and being able to introduce
patients to the idea of the trial before they came for their
Table 5 Facilitators, barriers and suggestions regarding the recruitment process (views of patients in "normal" typeface and views of
health professionals in "bold")
Facilitators Barriers Suggestions
(27) The process was straightforward, clear and
professional
(1) well organised packs
(4) Patients did not fully understand the process
(outcomes, confused if antibiotics were part of trial)
(3) Unclear how the results would indicate if
Pelargonium is effective when patients are also taking
other meds
(7) limited and confusing inclusion criteria (child-
bearing age)
• Better explain the use of antibiotics in relation to
the study medication
• have inclusion / exclusion cards
(26) Clinicians’ approach: helpful, informative,
reassuring & spent enough time to explain the trial
(2) quick recruitment session
(1) direct approach in waiting room
(4) Burden: time consuming for GP and patients,
paperwork and repetition of consent
(6) time consuming for GPs and nurses
(2) time consuming for patients
(3) too much pressure for primary care
(3) recruitment takes too long
• consent patients to trial once and remind them
that they agreed to be contacted, etc.
• warn participants about duration of recruitment
appointment
• approach patients when feeling better
• reduce paperwork for clinicians
• research nurses to run the trial and give them
protected time
• condense and simplify process and documents
• send member of HATRIC team/nurse to discuss
with patients before they see the GP
• run it outside primary care (e.g. A&E, walk-in
centres)
• separate the process (identification –
recruitment) and bring back patients
• remote consent and trial medicine
(22) Clear information on the PIS (3) Fear of side-effects
(6) long diary considered as burden
(1) severe adverse event
• recruit patients earlier in their illness
• GPs to explain the new drug and if harmless in
simple lay terms
• translate PIS in different languages
• make the font bigger
• make the diary more user-friendly
• bound it together better
• simplify and make it less busy
(22) Patients took part to help with research, reduce
Antibiotics use and try alternative ways
(2) patient willing to help with research
(3) Did not understand randomisation
(2) randomisation
• direct approach by the GP
(9) Wish/need to take something when Antibiotics not
appropriate
(2) Prescription of Antibiotics enabled some patients to
take part
(3) Offer of (delayed) Antibiotics
(2) If GP had not given them immediate Antibiotics,
they would not have considered taking part
• use simple terms and consistently: infection, cough,
bronchitis
(1) Vouchers were a good incentive
(1) Vouchers are good (but may not work in
affluent areas)
(5) equipoise (e.g. if too ill, woman of childbearing age)
(2) Clinician’s lack of equipoise: (under) report side effects
(1) GP described the trial as a ‘secondary thing’
• use an app for busy people
(8) patients’ positive views on herbal meds
(2) staff’s positive views on herbal medicine
(4) patients’ negative views on herbal medicine
(5) number of GPs and nurses actively involved in
the site
(1) not many staff involved train nurses to check eligibility
(1) patients’ high demographics (7) seasonal reasons (no eligible patients during
summer)
(4) patients would not bother GP for viral infections
(1) patients were beyond 3-week period
open trial in winter, run full season
(2) prompts from the system
(3) triage system
(2) introducing trial on the phone
(2) research-clinical parallel sessions
(3) first few recruitments were difficult
(2) surgery’s system (MAC nurse, multi-site)
(1) not having NHS.net account to send the forms
(4) not enough payment for GPs
• support the GPs and nurses for recruiting
the first 1–2 patients
• ensure 2nd recruit is soon after the 1st
• run parallel research – clinical sessions
• introduce trial when in reception
• a boost of money to motivate sites
monthly competition between sites
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appointment (over the phone or in the waiting room)
also helped, as did the option of offering delayed
antibiotics.
Trial medication
Overall the majority of participants reported that they
understood how and when to take the medication and
did not encounter any major issues (Table 6). The main
difficulties were side-effects and confusion around when
to start or stop the study medication. For example, one
participant stopped taking the study medication when
she started antibiotics because she thought she could
not take both together. Another stopped the medication
when he felt better and did not realise that he was sup-
posed to carry on for a few more days. Half of the inter-
viewees reported that they did not miss any doses, and
most of the others missed just one or two doses (consist-
ent with quantitative results, Table 2). Three patients
only took the trial medication for 2–3 days: the first one
stopped when he started the antibiotics and the other
two when they experienced severe nausea and sickness.
Another participant stopped taking the trial medication
when he felt better and later started again.
While most patients taking tablets did not notice a
particular taste, half of the participants taking the liquid
noticed a particular taste which was described as “bitter
–sour”, “unusual fruity”, “like it was a root extract… very
organic … a nice change”, “mildly strange”, “something
like Bach’s flowers rescue remedy”, “evil and gross”. Pa-
tients were asked whether they thought they had taken
the real trial medicine or the placebo. About a third of
patients thought they might have had the real medicine
(because of the unusual taste, because they felt better, or
had an adverse effect). About a third of patients thought
they might have had the placebo (because they did not
feel any improvement in their symptoms). Seven patients
had no idea and could not tell either way. Three patients
had not understood that they could be given a placebo.
“I am a bit worried about this dummy business. Are you
saying you are giving some people pills that you know
don’t work?”. Overall blinding appeared to be successful
in the 29 patients included in the qualitative study –
only 50% of those on active liquid, and fewer than 50%
in the other groups, correctly guessed their allocation,
no more than would be expected by chance. Almost all
based their guess on whether or not they felt they had
improved, rather than on the appearance or taste of the
medicine.
Although patients only received one formulation (li-
quid or tablets) they were asked which they would prefer
to receive. Six patients said that they would not mind ei-
ther. Four patients said that they would prefer the liquid
(because there is less pharmaceutical processing involved
than in manufacturing tablets, and the liquid felt
soothing for the throat). Fifteen said that they would
prefer tablets, because they were already taking other
tablets, tablets were easy to swallow, they were more
convenient, one is less likely to take the wrong dose,
there is no problem with spillage, they can be put in
a weekly container and they are easier to carry out.
The main reason for disliking the liquid was its taste.
Several patients reported problems in measuring the
liquid dose in drops and thought they may sometimes
have taken the wrong dose; they would have preferred
to measure the dose using a spoon. Two health pro-
fessionals expressed similar concerns about dosing the
liquid, but one reported that “I perceived a problem
but it wasn’t, it didn’t come to fruition actually… it’s
to do with number of drops and things, isn’t it, but it
wasn’t a problem” (HP02, GP).
Study diaries
The majority of patients said the study diaries were
clear, but it was obvious that not all understood or
completed them as requested (Table 7). While six
health professionals felt the diaries were straightfor-
ward, three felt they were too long and confusing,
and four told their patients not to take part in the
Table 6 Facilitators, barriers and suggestions regarding the trial medication (views of patients and health professionals)
Facilitators Barriers Suggestions
(17) would prefer tablets as are easier to take (10) missed doses • keep Antibiotics prescription separate from HATRIC
folder
• enhance the PIS to explain use of Antibiotics and trial
meds
(14) used strategies to remind them to take the
trial medication
(9) experienced side effects
(6) had difficulties with timing (30mins
before meals)
• Offer reminding strategies
• take medication with or after meal
(6) used strategies to dispense the liquid drops (6) had difficulties in dispensing the
drops
(3) had difficulties in measuring the
drops
• provide appropriate measure: dripper, small container,
teaspoon, top, etc.
• better ways of dispensing, explain about shaker bottle
• make it more concentrated
(1) nurse warned about the taste (5) reported unusual/unpleasant taste • improve the taste
• give only tablets
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trial unless they could commit to completing the
diaries. More than a third of the patients stopped
completing their diary prematurely, for example, four
when their trial medication finished, and two when
they started on antibiotics, because they did not real-
ise that they were expected to continue. Seventeen of
the interviewees had needed telephone support to
help them understand or complete the diary. Al-
though a majority preferred paper diaries, a small
number would have preferred an electronic version.
When prompted to discuss several parts of the diar-
ies, some participants mentioned that they found the
diary daunting, complex, and somewhat confusing.
Some felt confused because of the illness or just felt
too sick to complete the diary. The Quality of Life
questionnaire (EQ5D) elicited mixed views: almost
two thirds of the participants (n = 17) reported that it
was fine but nine participants found it difficult. Two
patients were unsure if it referred to the cough or
general health. One said it was “completely arbitrary”,
another said, “it’s a very generalised assessment. It all
depends whether you’re feeling cheerful on that day
for other reasons…”. Some participants suggested add-
ing more guidance: “100 means I’m up for running a
marathon down to 10 or 20 would be: can’t get out of
bed. Something like that, might just be helpful from
your point of view to keep things uniform”.
Overall views on trial procedures
Most interviewed health professionals felt that the trial
was well designed and organised (Table 8). A minority
felt that payments were insufficient, that the training
was too long, and that there were too many forms.
Discussion
Summary of main findings
We were able to recruit 24.7% (134/543) of patients
screened for inclusion into this study and 51% (134/261)
of those who were eligible. With telephone follow-up it
was possible to obtain the key outcome measures for
80%. We recruited 134/160 (84%) of the target sample
size however this was over a shorter recruitment period
and at a faster rate than predicted (15 patients per
month instead of 13). There was a low rate of with-
drawal and there were no safety concerns. The cluster
randomisation resulted in imbalance between the groups
as some GP practices were more likely to prescribe anti-
biotics. Most patients complied with the medication for
at least one week. Most of the patients interviewed were
happy with the study procedures and the study diary, al-
though there was some confusion about some sections
in the diaries and also whether and when they were ex-
pected to take antibiotics. The majority of patients inter-
viewed would have preferred tablets because of the taste
and inconvenience of the liquid preparation. Blinding
Table 7 Facilitators, barriers and suggestions regarding the trial diaries (views of patients and professionals)
Facilitators Barriers Suggestions
[24] Diary was clear and easy
[2] diary easy and
straightforward
[1] pre-paid envelope
[11] found the diary to be
daunting, wordy and complex
[10] stopped diary prematurely
[4] long, repetitive and
daunting initially
○ clearer instructions to continue, even when on antibiotics or end of treatment
and use big bold font
○ simpler and shorter layout (patients may be unwell) with fewer questions
○ offer yes/no answers
○ do not put tick boxes as people fill them inaccurately
○ change from 1 to 6 to 1–10 as more commonly used
○ could be simpler language
○ make the font bigger
○ make it more user-friendly
○ bind it together better
○ simplify and make it less busy
○ slim down the demographics
[16] EQ5D was easy [9] found the EQ5D difficult to
rate
○ give guidance how to complete EQ5D (e.g. 5 = you don’t have any energy to go
out to the shop, 100 = you feel you can walk up a mountain)
○ change EQ5D with a more objective measure, e.g. frequency of coughing,
amount & colour of phlegm (easier to remember and report) or ask, ‘do you feel
better today than 2 days ago?’
○ change EQ5D to 0–10 (too much scope otherwise)
[16] Phone calls from
research team were very
helpful
[2] missed some sections ○ be clear and remind patients about the trial when the trial team call them
○ more details on early pages on symptoms
○ call /text /email on last day of medicine to remind them to carry on with the
diaries
[12] Filling in the diary as you
go was helpful
○ follow logical order and split questions to have each day in one page/section
(DAY 1 on the top)
○ spread it out more
[8] Diary left in open view as
reminder
○ make the days bolder and bigger (not in tiny boxes)
[4] Had a routine ○ offer choice for diaries: paper or electronically
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appeared to be successful as only a minority of patients
interviewed correctly guessed their allocation to active
or placebo. Facilitators to recruitment included patients
having a positive attitude towards herbal medicine, a tri-
age system at the GP practice, introduction to the trial
before the GP appointment and the option of delayed
antibiotics. The main barriers to recruitment were con-
fusion about inclusion criteria, fewer suitable patients
during the summer, and perceptions that the recruit-
ment process was time-consuming, that the diary was
lengthy, and that the GP payment was insufficient.
Strengths and limitations
This is the first feasibility trial to be conducted on the
use of a herbal medicine for acute bronchitis in UK pri-
mary care. A strength of this trial is the use of both
quantitative and qualitative methods to explore several
feasibility aspects. The trial was not powered to detect
effectiveness, so we are unable to comment on the ef-
fectiveness of the herbal medicine. However, there was
no evidence of any serious side-effects due to the inter-
vention and the patient withdrawal rate was low. Al-
though the study was only open for 9 months as
opposed to the 12months initially planned, we recruited
at a faster rate than anticipated.
Limitations included a delay of up to 3 months be-
tween patients completing the trial and the qualitative
interview, so some interview participants could not recall
all details. When asking patients whether they preferred
liquid or tablets in the qualitative interviews, each pa-
tient had only tried one of these options. They were not
aware that the Cochrane review [30] suggests that the li-
quid may be more effective than tablets; knowing this
may have changed their responses.
Although patients suggested changes to the severity of
illness rating scale and to the EQ-5D-5L, it will not be
possible to make these changes in future trials because
these scales are only validated in their current format.
Restrictions on which type of contraception were used
by women were stringent and were misunderstood by
some of the GPs enrolling patients.
Implications for further research
Our results suggest that progression to a full randomised
phase III trial is feasible. The feasibility trial has identi-
fied some key modifications which will be needed. It
would be easier to choose only one formulation to test
(liquid or tablet). Although most patients reported that
they would prefer tablets, the Cochrane review [30] sug-
gested that the liquid may be more effective. If the liquid
is to be taken into a full trial, a more convenient dosage
method may need to be provided as many patients
struggled accurately to count 30 drops per dose. If a full
study uses both liquid and tablet preparations, we would
need to adapt the design to prevent imbalance in the
antibiotic use. This could be achieved by individual ran-
domisation (tablet/liquid/active/placebo) or through
stratification of practices according to prior antibiotic
prescribing history.
As this feasibility study was conducted in GP practices,
the future phase III trial should be in the same setting.
However, as several patients commented that they would
Table 8 Barriers and facilitators to trial procedures (views of health professionals)
Facilitators Barriers Suggestions
(8) Well designed and organised trial
(4) Well received by patients and clinicians
(1) Very difficult trial to run
(3) Storage was fine (2) Moving medicine between sites was difficult
(1) storing the medicine at the right temperature
(1) lack of space to store trial paperwork
(1) handling the medicine when arrived
• provide bigger folders
(2) Training was excellent (4) training was too long with too much detail
(1) training was long time ago
• cascade the training internally
• condense the training
• iron out the basics online
• deliver it nearer the time
(1) Electronic database worked well (2) online system difficult to use • change /review system
(3) Very clear paperwork for sites and patients
(1) coloured folder for the patients
(3) too many forms and repetitions • laminated checklists
(6) clear, speedy communication with study team (1) overzealous contacts
(1) complicated screening
(1) unsure about screening failures
• only report those who were almost recruited
• provide inclusion /exclusion cards
[4] payment was low
(1) chasing payments from HATRIC and CRN
(1) checking returned diaries • CTU to check diaries
(1) not having a NHS.net email account • post or fax the paperwork
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have preferred to start the herbal medicine earlier in
their illness there may be potential for a study in phar-
macies, to see whether we could also conduct a trial of
taking Pelargonium at an earlier stage in the illness, to
avoid the need to consult a GP and so to reduce use of
antibiotics.
Conclusions
The HATRIC study showed it is feasible and acceptable
to recruit and follow up patients with acute bronchitis
from UK primary care into a study of a herbal medicine
to facilitate reduction in antibiotic use. Progression to a
phase III trial is recommended.
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